Drugs / RISEVISTINEL
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04044664 | Jan 2019 → Aug 2020 | post-traumatic stress disorder | Aptinyx | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05181995 | Dec 2021 → Mar 2023 | post-traumatic stress disorder | Aptinyx | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05447286 Comparator | May 2023 → Dec 2024 | substance-related disorder | Yale University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RISEVISTINEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314589 ↗ |
| Known as | NYX-783 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05447286 ↗ |
| Modality | Small molecule | “NYX-783 is a small molecule” NCT04044664 ↗ |